Our analysis of transcriptional heterogeneity underscores the importance of targeted therapies that exploit biological vulnerabilities, such as the use of menin inhibitors in KMT2Ar or NPM1‐mutated leukemias [24], or combinatorial immunotherapeutic approaches [25] that span the diverse pAML landscape. This evidence concerns the gene NPM1 and leukemia.